1. Introduction
Recently, significant progress has been made in the development of engineered tissues for clinical applications including wound and burn repair. However, progress towards engineering complex tissues and organs has been limited by challenges in forming an integrated and functional vasculature. In highly metabolic organs such as the heart, lung and liver, capillaries must reach within 100–200 μm of each cell within the growing tissue to provide adequate gas, nutrient and metabolite exchange [
1]. Insufficient vascularization can lead to improper cell integration or cell death in engineered tissue constructs. While endogenous blood vessels can invade the implanted tissue enabling spontaneous blood vessel formation, the rate of neovascularization for millimeter-sized implants typically takes several weeks, such that clinically useful implants would not re-vascularize in a clinically-relevant timeframe [
2]. Thus, achieving a replacement tissue with a patent and sustainable microvasculature represents a key, rate limiting step in the formation of most replacement tissues or organ systems.
Methods for vascularization that would enable generation of highly metabolic replacement tissues comprise various pathways. One approach utilizes functionalized scaffold materials to induce or sustain the host’s angiogenic activity
in vivo. Here, highly permeable hydrogels or porous materials have been utilized as scaffold matrices, not only to increase bulk diffusion of oxygen and nutrients, but also to encourage vessel infiltration [
3,
4]. Both the mechanical stability and the high degree of pore interconnectivity required represent challenges for these approaches. In addition to scaffold mechanical and structural properties, this approach elicits localized angiogenesis through the use of bio-active scaffolds which have been chemically derivatized by incorporating angiogenic inducers,
i.e., small molecules, growth factors or extracellular matrix components that can be released locally and stimulate angiogenesis
in situ [
5]. Use of chemical signals to promote vascularization has resulted in the successful formation of capillary beds in both synthetic and naturally-occurring materials [
6]. However, robustness and stability of nascent capillary beds generated using these growth-factor-based approaches remain a concern.
A second general approach toward achieving tissue vascularization involves precisely engineering three dimensional matrices with microfluidic conduits that mimic the tissue-specific features of the endogenous microcirculation. In this case the scaffold material provides the physical template needed to organize cells into a functional microvasculature, achieving patency and enabling engineered tissue- or organ sustainability. In this regard, the microfluidic network enables mass transfer of nutrients in exchange for metabolites and waste from the scaffold. Furthermore, mechanical forces and cues such as fluid shear can be designed within the microfluidic network to insure healthy tissue- or organ-specific physiology. Three dimensional tissue scaffolds containing an engineered microvasculature have been fabricated from a number of biocompatible polymers. The capabilities of soft lithography and polymer-based BioMicroElectroMechanical systems (BioMEMS) have provided tools for the fabrication of biocompatible polymer systems. Previously reported materials used for three dimensional scaffold molding include polydimethylsiloxane (PDMS) [
7], polycaprolactone (PCL) [
8], poly(lactic-co-glycolic acid) (PLGA) [
9,
10], and polyglycerol sebacate (PGS) [
11,
12,
13]. Other approaches [
14] have demonstrated vascularization of tissues such as skeletal muscle tissue by seeding endothelial cells in a vascularized construct, which, after implantation, led to attraction of host blood vessels towards the engineered construct.
For
in vivo applications, there are several critical scaffold properties required in order to properly support microvascular development. Mechanically, the material must have high tensile strength while providing a flexible and elastomeric structure [
15]. It is also important that fabrication of the scaffold should involve mild processing conditions that can be carried out relatively simply, reliably, and inexpensively. To perform
in vivo, microvascular scaffolds must be biocompatible, non-thrombogenic, and resistant to infection [
16]. In addition, scaffolds must promote cellular adhesion, cell growth, and retention of differentiated cell types or contain chemical moieties for modification to do such. Finally, the material should also be designed to degrade at a rate that is compatible with the time required to achieve mechanical integrity while enabling microvascular stabilization and patency.
Here, we investigate silk fibroin as a suitable biomaterial for the construction of a biodegradable microvascular scaffold. Purified from the domesticated silk worm
Bombyx mori, silk fibroin has been extensively characterized and proven effective in clinical applications [
17] as early as forty years ago for surgical sutures [
18]. Silk fibroin continues to be the subject of intensive investigation for numerous biomedical applications [
19,
20,
21,
22]. An important recent development was the discovery that sericin (the glue like protein which accounts for 20–25% by weight of the silk produced by silkworms and can be biochemically separated from the silk fibroin, itself) was responsible for the inflammatory responses observed in native silk. By extracting the residual sericin from silk fibroin, a suitable non-immunogenic biomaterial can be formed. In addition to its low immunogenicity, silk fibroin purified from
B. mori cocoons demonstrates superior mechanical strength and elastic properties compared with virtually all other biopolymers [
23]. Further, the availability of amine and acid side chains on the silk fibroin protein, itself, make chemical or covalent modification with a vast number of conjugating or functionalizing reagents possible. This allows for a tailoring of the silk material that might foster site- and or cell-specific microdomains offering optimized scaffold environments required for normal cell growth, differentiation and tissue morphogenesis. Silk fibroin is also biodegradable via proteolysis; and, the degradation rate can be precisely tuned. For example, during the first five day period of enzyme exposure, a pure silk fibroin film loses roughly 10% of its original mass, followed by an extended period of slow degradation lasting 1 to 2 years [
24]. Slow degradation
in vivo is ideal as it allows for the gradual incorporation of native cells as the implanted structure is slowly removed [
17]. Silk is also an FDA approved biomaterial. The dense, nonporous nature of the silk scaffold we are reporting serves only as an initial demonstration vehicle for this technology, and therefore the porosity and structural properties of future silk scaffolds may also be tuned to provide more ideal transport properties and cell-cell communication in the engineered tissue constructs. Thus, the inherent properties and tenability of silk fibroin make it an ideal candidate for implantation as a microvascularizing scaffold biomaterial. Building on the initial demonstration of a silk-based microfluidic system for tissue constructs [
15], this is the first report of a non-inflammatory, non-immunogenic high-strength silk fibroin based microvascular scaffold.
3. Experimental Section
3.1. Preparation of Silk Solution
Aqueous silk fibroin solutions were made using a modified extraction procedure of
B. mori cocoons based on methods previously described [
27]. Sectioned silk cocoons were boiled for 45 minutes in an aqueous solution of 0.2M Na
2CO
3 to extract sericin proteins. The purified silk fibroin was then washed thoroughly with de-ionized (DI) water and allowed to dry overnight at ambient conditions. The silk fibroin was then dissolved in aqueous 9.3 M LiBr at 60 °C for 4 hours. The resulting solution was dialyzed against DI water using a Slyde-a-lyzer cassette with a 3,500 MWCO for a period of 48 hours [
26]. The resultant silk fibroin solution (aqueous 6–8% weight/weight; w/w) was further concentrated by a reverse dialysis method using 30 wt % poly(ethylene glycol) (PEG) [
27,
28]. The final working silk fibroin solution 10–13% (w/w) was then available for scaffold fabrication.
3.2. Silk Microvascular Network Scaffold Fabrication
The design of the microvascular channels were carefully chosen to mimic a terminally branched microvascular perfusion circuit observed within specific organ systems, e.g. human dermal microvasculature. However, both branched bifurcated terminal microvascular networks or collateralized networks can be fashioned so that the entrance channels measure 1265 µm in width, which can branch or bifurcate evenly. In the studies described, herein, entrance channels have been designed to bifurcate 3 times in series creating channels of width 600, 350 and 200 µm respectively. These channel widths were reproduced quite closely in the actual silk scaffold; contraction/expansion of the structure upon silk molding was limited to a few percent or less. Smaller channels were considered, but were reserved for future studies due to challenges associated with seeding microchannels with dimensions close to those of capillaries. In addition, the fabrication mask and design layout were engineered to include pillar-like posts; structures that are spaced throughout the microchannel pathways, aimed at ensuring channel patency during the layer bonding process. These design iterations included round and oval pillars, which also provide additional surface area for cell attachment as shown (
Figure 5).
Figure 5.
(A) Design of multiple bifurcated networks, (B) Detailed layout of network with supporting posts, (C) Magnified view of bifurcation.
Figure 5.
(A) Design of multiple bifurcated networks, (B) Detailed layout of network with supporting posts, (C) Magnified view of bifurcation.
Channel layouts were created using microfabrication software (L-Edit, Tanner Research, Monrovia CA) and printed onto transparent flexible photomasks using a laser printer with 5080 dpi resolution (Pageworks). These photomasks were used to transfer microchannel network patterns into SU-8 2000 photoresist (Microchem, Newton MA) coated 100mm silicon wafers using a mask aligner (Karl Suss, Waterbury VT). The height of the SU-8 layer determines the depth of the microchannels, and is governed by the specific SU-8 product and the spin speed during SU-8 deposition on the wafers. Lithographic masters are postbaked and then surface-treated to enable mold release using a Teflon-like coating layer deposited in a reactive ion etcher (STS, Newport UK). The wafer patterns were then transferred to poly-dimethylsiloxane (PDMS) by casting a 10:1 mix of polymer:curing agent of Sylgard 184 (Dow Corning, Midland MI) onto the wafer and curing for 3 h at 65 °C. The PDMS inverse mold was then peeled off the silicon wafer.
For creating branched bifurcated microchannel networks in silk fibroin, purified and concentrated silk solution was cast over both the microchannel inverse PDMS mold as well as a flat section of PDMS and allowed to dry for 48 hours at ambient conditions. Flat sections were cut from the molded silk layers to avoid working with curved areas near the edge of the film. Silk films were removed from their PDMS mold and treated with 50% volume/volume(v/v) methanol in water for 4 hours to increase the beta sheet content and therefore the water stability [
26] prior to a final DI water wash (1 hr at room temperature, RT). Microfluidic devices were then formed by joining microchannel and flat silk films, and two flexible tip needles (for entry and exit flow). The entire stack, which includes a bonding solution of aqueous 6 wt % silk deposited by spinning or dip-coating at the interface is then laminated under pressure at 70 °C for 18 hours [
15]. When applied with the appropriate thickness, the bonding solution did not substantially affect the geometry of any of the microchannels in the network. The devices were removed from the bonding process and anchored between two glass microscope slides to create a controlled culture environment. UV sterilization can then be readily accomplished
3.3. Cell Culture
All cell culture reagents were purchased from GIBCO (Carlsbad, CA) unless otherwise noted. Well characterized human dermal microvascular endothelial cells (HDMVECs) were cultured with Dulbecco’s modified Eagles media (DMEM) supplemented with 5–10% fetal bovine serum, 1% penicillin streptomycin fungizone antimyotic (PSF), and 2.5 mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) [
29]. Experiments were performed using media containing 5–10% serum with no significant impact on endothelial proliferation. Passage 7–10 cells used for experiments were cultured at 37 °C and 5% CO
2 with fresh media supplied twice per week during growth. HDMVECs were allowed to remain one day post-confluent HDMVEC cultures were harvested by trypsinization (Trypsin/EDTA, GIBCO, Carlsbad, CA) as previously reported [
28,
29].
3.4. Cell Seeding
Immediately following trypsinization, the HDMVEC cell pellet was suspended to a concentration of 1 × 10
6 cells/mL in growth media supplemented with 10ng/mL of basic fibroblast growth factor (bFGF) and platelet derived growth factor (PDGF-BB) to enhance cell proliferation after seeding [
29]. Two hours prior to trypsinization and HDMVEC re-suspension, the channels of the silk microdevices were saturated with supplemented media and allowed to condition for 2 hours. The concentrated cell solution was then dropped into fluidic connections just before the entrance needle to the device. Behind the cell solution a media line was connected and pushed by syringe pump (Harvard Apparatus, Holliston MA) at a flow rate of 5 μL/min until cells were visible inside the device. Cells were allowed 16 hours of static attachment at 37 °C and 5% CO
2 before initiation of media perfusion (1 μL/min).
3.5. Cell Staining
Flat sections of silk, used as a static control in order to enable full visualization of the endothelial layer, with attached HDMVEC cells were fixed and permeabilized to facilitate cytoplasmic and nuclear localization of F-Actin (Alexa586- Phalloidin (Molecular Probes, OR) and DNA (Hoechst, Molecular Probes, OR) In this way, cellular colonization within the branched bifurcated microchannel networks could be evaluated and cellular morphology simultaneously assessed. Media was aspirated from the cell culture and films were washed three times with PBS prior to fixation at room temperature 3.7% v/v formaldehyde (Sigma-Aldrich, St. Louis, MO) for 10 minutes. The fixative solution was removed and the films were again washed three times with PBS prior to permeabilization with 0.1% v/v Triton in PBS for 5 minutes. Following permeabilization, cell containing films were again rinsed with PBS three times. To prevent non-specific staining, films were incubated with 1% BSA in PBS (Sigma-Aldrich, St. Louis, MO) solution for 20 minutes at room temperature. The BSA solution was aspirated and 0.165 µM phalloidin (Invitrogen Molecular Probes, Eugene, OR) was added and allowed to incubate for 20 minutes at room temperature while protected from light. The cell containing films were again washed with PBS three times. Next, Hoechst 33342 (Invitrogen Molecular Probes, Eugene, OR) at 2 µg/mL in PBS was added and allowed to incubate for 20 minutes at room temperature while also protected from light. Finally, the Hoechst solution was aspirated and the films were washed with PBS prior to light microscopic imaging.